Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (HIV-CORE 002)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01151319
First received: June 24, 2010
Last updated: April 29, 2014
Last verified: April 2014
  Purpose

This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.


Condition Intervention Phase
HIV-1 Infections
Biological: ChAdV63.HIVconsv low dose.
Biological: ChAdV63.HIVconsv high dose.
Biological: pSG2.HIVconsv
Biological: MVA.HIVconsv
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Safety [ Time Frame: Actively collected data throughout the study until 6 months after the last vaccination ] [ Designated as safety issue: Yes ]
    Proportion of volunteers who develop a grade 3 or 4 local reaction.


Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: Samples will be collected at every visit pre- and post vaccination ] [ Designated as safety issue: No ]
    Proportion of volunteers who develop new CD8+ and CD4+ T cell responses to one or more HIV-1 epitopes, as determined by IFN-γ ELISPOT assay.

  • Immunogenicity [ Time Frame: Stage 1; screen, 0, 1, 2, 4, 8, 16, 28 wk. Stage 2; screen, 0, 1, 2, 4, 8, 9, 12, 20, 28 wk. Stage 3; screen, 1, 8, 12, 13, 14, 20, 21, 22, 28 wk. Stage 4; screen, 0, 8, 12, 13, 16, 17, 18, 24, 28 wk post vac. Stage 2 & 3: 6,12,24 mth after last vaccine ] [ Designated as safety issue: No ]
    Exploration of the efficacy of vaccine-induced CD8+ T cells to suppress HIV-1 replication in vitro.


Enrollment: 32
Study Start Date: October 2010
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stage 1.
The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
Biological: ChAdV63.HIVconsv low dose.
Attenuated chimp adenovirus. 5x10^9 virus particles.
Experimental: Stage 2
The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
Biological: ChAdV63.HIVconsv high dose.
Attenuated chimp adenovirus at 5x10^10 virus particles.
Biological: MVA.HIVconsv
Attenuated poxvirus at 4x10^8 plaque forming units per dose.
Experimental: Stage 3
Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
Biological: ChAdV63.HIVconsv high dose.
Attenuated chimp adenovirus at 5x10^10 virus particles.
Biological: pSG2.HIVconsv
DNA at 4mg per dose.
Biological: MVA.HIVconsv
Attenuated poxvirus at 4x10^8 plaque forming units per dose.
Experimental: Stage 4
Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
Biological: ChAdV63.HIVconsv high dose.
Attenuated chimp adenovirus at 5x10^10 virus particles.
Biological: pSG2.HIVconsv
DNA at 4mg per dose.
Biological: MVA.HIVconsv
Attenuated poxvirus at 4x10^8 plaque forming units per dose.
Placebo Comparator: Stage 2 Placebo
Time-course matched to vaccinations (n=2)
Other: Placebo
Phosphate buffered saline
Placebo Comparator: Stage 3 placebo
Time-course matched to vaccinations (n=2)
Other: Placebo
Phosphate buffered saline
Placebo Comparator: Stage 4 placebo
Time-course matched to vaccinations (n=2)
Other: Placebo
Phosphate buffered saline

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males or females, as assessed by a medical history, physical examination and laboratory tests.
  2. Aged at least 18 years on the day of screening and no greater than 50 years on the day of the first vaccination.
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  4. In the opinion of the principal investigator or designee, the volunteer has understood the information provided. Written informed consent must be given before any study-related procedures are performed.
  5. Willing to undergo HIV-1 testing, HIV-1 counselling and receive HIV-1 test results.
  6. If heterosexually active female; using an effective method of contraception (e.g. hormonal contraception, diaphragm, intra-uterine device (IUD), condoms, anatomical sterility in self or partner) from 14 days prior to the first vaccination until at least 6 weeks after the last vaccination; all female volunteers must be willing to undergo urine pregnancy tests at time points specified in the protocol.
  7. If heterosexually active male; willing to use an effective method of contraception (condoms; anatomical sterility in self or partner) from the day of the first vaccination until 6 weeks after the last vaccination.
  8. Willing to forgo donations of blood during the study.

Exclusion Criteria:

  1. Any clinically significant acute or chronic medical condition that is considered progressive or, in the opinion of the principal investigator or designee, would make the volunteer unsuitable for the study.
  2. Any of the following abnormal laboratory parameters listed below:

    Haematology

    • Haemoglobin < 10.0 g/dl
    • Absolute Neutrophil Count (ANC) ≤ 1000 /mm3 (≤ 1 x 109 /l)
    • Absolute Lymphocyte Count (ALC) ≤ 600 /mm3 (≤ 1 x 109 /l)
    • Platelets ≤100,000 /mm3, ≥ 550,000 /mm3 (≤ 90 /l, ≥ 550 /l) Biochemistry
    • Creatinine > 1.3 x ULN
    • Aspartate aminotransferase (AST) > 2.5 x ULN
    • Alanine aminotransferase (ALT) > 2.5 x ULN Urinalysis
    • Abnormal dipstick confirmed by microscopy
  3. Reported high-risk behaviour for HIV infection. High-risk behaviour for HIV-1 infection is defined as follows. Within the previous 6 months the volunteer has:

    • Had unprotected vaginal or anal sex with a known HIV-infected person or a casual partner (i.e., no continuing, established relationship)
    • Engaged in sex work for money or drugs
    • Used injection drugs
    • Acquired one of the following sexually transmitted disease (STD); Chlamydia, gonorrhoea and syphilis.
  4. Confirmed HIV-1 or HIV-2 infection.
  5. If female, pregnant or planning a pregnancy within 6 weeks after last vaccination; or lactating.
  6. Receipt of live attenuated vaccine within the previous 60 days (live attenuated flu vaccine within 14 days) or planned receipt within 60 days after vaccination with Investigational Product or receipt of other vaccine within the previous 14 days or planned receipt within14 days after vaccination with Investigational Product.
  7. Receipt of blood transfusion or blood products within the previous 6 months.
  8. Participation in another clinical trial of an Investigational Product currently, within the previous 3 months or expected participation during this study.
  9. Receipt of any investigational HIV vaccine within the last 6 years.
  10. History of severe or very severe local or systemic reactogenicity events, or history of severe or very severe allergic reactions.
  11. Confirmed diagnosis of hepatitis B virus (surface antigen, HBsAg), hepatitis C virus (HCV antibodies) or active syphilis.
  12. Smallpox vaccination within the previous 3 years (smallpox vaccination prior to 3 years should be documented but is not an exclusion criterion).
  13. Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, suicidal attempt or ideation in the previous 3 years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01151319

Locations
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine
Oxford, Oxon, United Kingdom, OX3 9DZ
Sponsors and Collaborators
University of Oxford
Investigators
Principal Investigator: Tomas Hanke University of Oxford
Principal Investigator: Lucy Dorrell University of Oxford
  More Information

No publications provided by University of Oxford

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01151319     History of Changes
Other Study ID Numbers: HIV-CORE 002
Study First Received: June 24, 2010
Last Updated: April 29, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

ClinicalTrials.gov processed this record on August 28, 2014